Abstract Platinum and poly (ADP-ribose) polymerase (PARP) inhibitors are cornerstone therapies for ovarian cancer (OC), and their efficacy relies on homologous recombination deficiency (HRD), leaving more than 50% of HRD-negative OC patients with limited treatment options. This study investigated the epigenetic regulator, Polycomb Repressive Complex 2 (PRC2), as both a potential modulator of homologous recombination (HR) status and a candidate therapeutic target in ovarian cancer.
